RANI
$1.31
Rani Therapeutics Holdings, Inc.
Recent News
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 105.13% +2.83, GraniteShares 1.5x Long COIN Daily ETF (CONL) 11.48% +0.83, Icici Bank (IBN) 1.10% +0.80, EETH ETF (EETH) 19.93% +0.59, Tradr 2X Long IREN Daily ETF (IREX) 24.34% +0.56, iShares Investment Grade Corporate Bond ETF (LQD) 3.00% +0.55, Beyond Meat (BYND) 12.97% +0.49, Rani Therapeutics Holdings (RANI) 18.04% +0.44, Direxion Daily 20 plus Year Treasury Bear
Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%
Key Insights Rani Therapeutics Holdings' significant retail investors ownership suggests that the key decisions are...
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes that the company has 3 major value drivers: the platform technology RaniPill, a recent […]
Trending tickers: Apple, Beyond Meat, Rani Therapeutics, BitMine and B&M
The latest investor updates on stocks that are trending on Monday.
Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost
Rani Therapeutics Holdings (RANI) has grabbed attention after announcing a collaboration and license agreement with Chugai Pharmaceutical for an oral rare disease therapy. The deal includes payments tied to development milestones as well as future product commercialization. See our latest analysis for Rani Therapeutics Holdings. Rani Therapeutics’ share price has skyrocketed over 240% in the past month following its blockbuster deal with Chugai and a $60 million financing round, demonstrating...